Key facts
| Price (PPV) | 300 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | levodopacarbidopaentacapone |
| Class | Anti-parkinson drugs |
| ATC code | N04BA03 |
| Manufacturer | NOVARTIS PHARMA MAROC |
| Presentation | Boîte de 30 |
| Hospital price | 199.90 MAD |
| Data collected on | 9/8/2026 |
Indications
Stalevo est destiné au traitement des patients adultes atteints de la maladie de Parkinson et présentant des symptômes de fluctuations motrices (appelés de fin de dose ou symptômes on-off) qui ne peuvent être stabilisées avec l'association lévodopa/inhibiteur de la dopa décarboxylase. Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About Stalevo 50 mg / 12.5 mg / 200 mg
Stalevo 50 mg / 12.5 mg / 200 mg belongs to the anti-parkinson drugs therapeutic class. In Morocco, this drug is marketed by NOVARTIS PHARMA MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Stalevo 50 mg / 12.5 mg / 200 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Stalevo 50 mg / 12.5 mg / 200 mg
Answers to common questions from Moroccan patients about this drug.